Lanthanum Carbonate Reduces Urine Phosphorus Excretion: Evidence of High-Capacity Phosphate Binding

REFERENCES

• Goodman WG, Goldin J, Kuizon BD, . Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–1483.
   PubMed Web of Science ®Google Scholar
• Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15(7):1014–1021.
   PubMed Web of Science ®Google Scholar
• Bellinghieri G, Santoro D, Savica V. Emerging drugs for hyperphosphatemia. Expert Opin Emerg Drugs. 2007;12(3):355–365.
   PubMed Web of Science ®Google Scholar
• Albaaj F, Hutchison AJ. Lanthanum carbonate (Fosrenol): A novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. Int J Clin Pract. 2005;59(9):1091–1096.
   PubMedGoogle Scholar
• Burke SK, Slatopolsky EA, Goldberg DI. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant. 1997;12(8):1640–1644.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Rix M, Fan S, . Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3(4):1125–1130.
   PubMed Web of Science ®Google Scholar
• Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci. 2007;96:2818–2827.
   PubMed Web of Science ®Google Scholar
• Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74(2):148–157.
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218.
   PubMed Web of Science ®Google Scholar
• Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(5):1423–1429.
   PubMedGoogle Scholar
• Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl. 3):1–201.
   Google Scholar
• Kidney Disease Outcomes Quality Initiative. KDOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2000;35(6):S17–S104.
   Google Scholar
• Ramirez JA, Emmett M, White MG, . The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int. 1986;30(5):753–759.
   PubMedGoogle Scholar
• Moshfegh A, Goldman J, Ahuja J, Rhodes D, LaComb R. What We Eat in America, NHANES 2005–2006: Usual Nutrient Intakes from Food and Water Compared to 1997 Dietary Reference Intakes for Vitamin D, Calcium, Phosphorus and Magnesium. Washington, DC: US Department of Agriculture, Agricultural Research Service; 2009.
   Google Scholar
• Sherman RA, Mehta O. Phosphorus and potassium content of enhanced meat and poultry products: Implications for patients who receive dialysis. Clin J Am Soc Nephrol. 2009;4(8):1370–1373.
   PubMed Web of Science ®Google Scholar
• Sheikh MS, Maguire JA, Emmett M, . Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest. 1989;83(1):66–73.
   PubMed Web of Science ®Google Scholar
• Gutierrez OM, Isakova T, Smith K, Epstein M, Patel N, Wolf M. Racial differences in postprandial mineral ion handling in health and in chronic kidney disease. Nephrol Dial Transplant. 2010;25(12):3970–3977.
   PubMed Web of Science ®Google Scholar
• Kimlin MG. Geographic location and vitamin D synthesis. Mol Aspects Med. 2008;29(6):453–461.
   PubMedGoogle Scholar
• Sherman RA. Dietary phosphate restriction and protein intake in dialysis patients: A misdirected focus. Semin Dial. 2007;20(1):16–18.
   PubMedGoogle Scholar
• Lau AH, Kuk JM, Franson KL. Phosphate-binding capacities of calcium and aluminum formulations. Int J Artif Organs. 1998;21(1):19–22.
   PubMedGoogle Scholar
• Heinrich T, Heidt H, Hafner V, . Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function. Nephrol Dial Transplant. 2008;23(9):2861–2867.
   PubMedGoogle Scholar
• Shire Pharmaceuticals. FOSRENOL (lanthanum carbonate) Prescribing Information. Wayne, PA: Shire US Inc.; 2011.
   Google Scholar
• Genzyme Corporation. Renagel (sevelamer hydrochloride) Prescribing Information. Cambridge, MA: Genzyme Corporation; 2007.
   Google Scholar
• Nabi Biopharmaceuticals. PhosLo (calcium acetate) Package Insert. Rockville, MD: Nabi Pharmaceuticals; 2003.
   Google Scholar
• Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089–1096.
   PubMed Web of Science ®Google Scholar
• Birge SJ, Peck WA, Berman M, Whedon GD. Study of calcium absorption in man: A kinetic analysis and physiologic model. J Clin Invest. 1969;48:1705–1713.
   PubMed Web of Science ®Google Scholar